Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
Rhea-AI Summary
Eton Pharmaceuticals (Nasdaq: ETON), a company focused on rare disease treatments, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York City. The company's CEO, Sean Brynjelsen, will deliver a presentation that will be available on demand starting September 9, 2024, at 7am ET.
Investors can access the presentation online, and those interested in in-person meetings with the company are encouraged to contact H.C. Wainwright's Corporate Access team. This event provides Eton Pharmaceuticals with an opportunity to showcase its innovative approach to developing and commercializing treatments for rare diseases to a global investment audience.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ETON gained 6.82%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
DEER PARK, Ill., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that the Company will participate at the H.C. Wainwright 26th Annual Global Investment Conference in New York City.
The Company’s presentation by Sean Brynjelsen, Chief Executive Officer, will be available on demand commencing on September 9, 2024, at 7am ET.
Investors can access the presentation here.
To schedule an in-person 1x1 meeting with the Company, please contact Corporate Access at H.C. Wainwright.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has five commercial rare disease products: ALKINDI SPRINKLE®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals.
FAQ
When is Eton Pharmaceuticals (ETON) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for Eton Pharmaceuticals (ETON) at the H.C. Wainwright conference?
How can investors access Eton Pharmaceuticals' (ETON) presentation at the H.C. Wainwright conference?
Where is the H.C. Wainwright Global Investment Conference being held in 2024?
What is the focus of Eton Pharmaceuticals' (ETON) business?
